GSK press releases Follow GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026 https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/ gsk.com
